NASDAQ:PVLA Palvella Therapeutics Q2 2026 Earnings Report $142.47 +18.32 (+14.76%) As of 10:57 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Palvella Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.16Beat/MissN/AOne Year Ago EPSN/APalvella Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APalvella Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Palvella Therapeutics Earnings HeadlinesPalvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% - Still a Buy?July 19 at 4:21 AM | americanbankingnews.comPalvella Therapeutics Corporate Event Calendar | NASDAQ:PVLAJuly 18 at 6:04 PM | benzinga.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.July 21 at 1:00 AM | Banyan Hill Publishing (Ad)Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 18 at 3:15 AM | americanbankingnews.comPalvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORINJuly 15, 2026 | insidermonkey.comPalvella Therapeutics Adds Industry Veteran to BoardJune 30, 2026 | tipranks.comSee More Palvella Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Palvella Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palvella Therapeutics and other key companies, straight to your email. Email Address About Palvella TherapeuticsPalvella Therapeutics (NASDAQ:PVLA) (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs. Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes. Utilizing its integrated chemistry and biology capabilities, the company seeks to optimize drug candidates for favorable pharmacokinetics, safety, and efficacy profiles. Palvella has also established strategic partnerships with academic institutions and industry collaborators to accelerate its research and development efforts. Headquartered in the United States, Palvella Therapeutics operates a dedicated research and development center where its multidisciplinary team of experts in immunology, medicinal chemistry, and clinical sciences drives program advancement. Since its inception, the company has demonstrated a commitment to expanding its pipeline through both internal discovery and external collaborations, with the ultimate goal of bringing new treatment options to patients suffering from debilitating inflammatory diseases.View Palvella Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
